sponsored
PatientsVille.com Logo

PatientsVille

Dianben Medical Research Studies

Up-to-date List of Dianben Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Dianben Medical Research Studies

Rank Status Study
1 Recruiting A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo to Ertugliflozin;   Other: Glimepiride;   Drug: Placebo to Glimepiride;   Biological: Basal Insulin;   Drug: Metformin
Outcome Measures: Change from Baseline in Hemoglobin A1c;   Number of Participants Experiencing An Adverse Event (AE);   Number of Participants Discontinuing Study Treatment Due to an AE;   Change from Baseline in Fasting Plasma Glucose;   Change from Baseline in Body Weight at Week 26;   Number of participants with a HbA1c of <7% (53 mmol/mol) at Week 26;   Change from Baseline in Systolic Blood Pressure;   Change from Baseline in Diastolic Blood Pressure;   Change from Baseline in Bone Mineral Density at Week 26;   Change from Baseline in Bone Mineral Density at Week 52;   Change from Baseline in Bone Mineral Density at Week 104;   Number of participants with HbA1c <=6.5% (48 mmol/mol) at Week 26;   Number of participants requiring glycemic rescue therapy up to Week 26;   Time to glycemic rescue therapy up to Week 26;   Change from baseline in bone biomarkers at Week 26;   Change from baseline in bone biomarkers at Week 52;   Change from baseline in bone biomarkers at Week 104
2 Recruiting A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (10 mg);   Drug: Placebo to Ertuglifozin;   Drug: Metformin;   Drug: Placebo to Metformin
Outcome Measures: Change from Baseline In Hemoglobin A1c (HbA1c) at Week 26;   Number of Participants Experiencing An Adverse Event (AE);   Number of Participants Discontinuing Study Treatment Due to an AE;   Change from Baseline in Fasting Plasma Glucose (FPG) at Week 26;   Change from Baseline in Body Weight at Week 26;   Number of Participants with a HbA1c <7% (53 mmol/mol) at Week 26;   Change from Baseline in 2-hour Post-prandial Plasma Glucose at Week 26;   Change from Baseline in Systolic Blood Pressure at Week 26;   Change from Baseline in Diastolic Blood Pressure at Week 26

These studies may lead to new treatments and are adding insight into Dianben etiology and treatment.

A major focus of Dianben research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Dianben